EU/3/15/1553

About

On 9 October 2015, orphan designation (EU/3/15/1553) was granted by the European Commission to Kite Pharma UK, Ltd, United Kingdom, for autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor for the treatment of primary mediastinal large B-cell lymphoma.

The sponsorship was transferred to Kite Pharma EU B.V., Netherlands, in April 2017.

This medicine is now known as axicabtagene ciloleucel.

Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor for treatment of primary mediastinal large B-cell lymphoma has been authorised in the EU as Yescarta since 23 August 2018.

Key facts

Active substance
Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)
Medicine name
Yescarta
Disease / condition
Treatment of primary mediastinal large B-cell lymphoma
Date of first decision
09/10/2015
Outcome
Positive
EU designation number
EU/3/15/1553

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Yescarta at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.

More information is available in the PDF iconorphan medicine assessment report .

Sponsor's contact details

Kite Pharma EU B.V.
Science Park 408
1098 XH Amsterdam
The Netherlands
Tel. +31 20 235 2630
E-mail: regulatory@kitepharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating
Average
1 rating